SEC 13F Intelligence

Birchview Capital, LP / CYTK

Birchview Capital, LP’s Cytokinetics Inc Position

Does Birchview Capital, LP own Cytokinetics Inc (CYTK)? Yes30.0K shares worth $2M (+1.13% of its 13F portfolio) as of Q1 2026.

Position Value
$2M
Q1 2026
Shares
30.0K
% of Portfolio
+1.13%
Quarters Held
24
currently held

Position History CYTK

Reported value by quarter
Q4 ’18: $63,000Q4 ’18Q1 ’19: $81,000Q2 ’19: $113,000Q3 ’19: $114,000Q3 ’19Q2 ’21: $198,000Q3 ’21: $894,000Q4 ’21: $1MQ4 ’21Q1 ’22: $920,000Q2 ’22: $982,000Q3 ’22: $1MQ3 ’22Q4 ’22: $1,146Q1 ’23: $880Q2 ’23: $815,500Q2 ’23Q3 ’23: $736,500Q4 ’23: $2MQ1 ’24: $701,100Q1 ’24Q2 ’24: $541,800Q3 ’24: $528,000Q4 ’24: $470,400Q4 ’24Q1 ’25: $401,900Q2 ’25: $330,400Q3 ’25: $2MQ3 ’25Q4 ’25: $2MQ1 ’26: $2Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202630.0K$2M+1.13%
Q4 202530.0K$2M+1.12%
Q3 202530.0K$2M+1.24%
Q2 202510.0K$330,400+0.33%
Q1 202510.0K$401,900+0.35%
Q4 202410.0K$470,400+0.38%
Q3 202410.0K$528,000+0.46%
Q2 202410.0K$541,800+0.50%
Q1 202410.0K$701,100+0.57%
Q4 202325.0K$2M+1.64%
Q3 202325.0K$736,500+0.63%
Q2 202325.0K$815,500+0.61%
Q1 202325.0K$880+0.69%
Q4 202225.0K$1,146+0.81%
Q3 202225.0K$1M+0.85%
Q2 202225.0K$982,000+0.71%
Q1 202225.0K$920,000+0.66%
Q4 202125.0K$1M+0.74%
Q3 202125.0K$894,000+0.61%
Q2 202110.0K$198,000+0.12%
Q3 201910.0K$114,000+0.08%
Q2 201910.0K$113,000+0.07%
Q1 201910.0K$81,000+0.05%
Q4 201810.0K$63,000+0.06%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Birchview Capital, LP’s full portfolio or all institutional holders of CYTK.